Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Neuroblastoma: early-phase trial registry
7 of 10 indexed Refractory Neuroblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 7 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Refractory Neuroblastoma: 10 US clinical trials tracked, 7 recruiting.
Refractory Neuroblastoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Stephan Grupp MD PhD, running 2 of these trials.
Enrollment posture brief
Registry condition refractory-neuroblastoma
OPEN 7 | RECR 70% | LATE 0 | EARLY 10 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)
Refractory Neuroblastoma lists 7 open slots (70% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Neuroblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Neuroblastoma is recruiting above its size-band peers.
7 of 10 indexed trials (70%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Neuroblastoma research.
Stephan Grupp MD PhD accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Neuroblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 10 trials that report a genuine target (sentinel values excluded). 10 of those (100%) plan for fewer than 100 participants.
-
Refractory Neuroblastoma research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Theodore Laetsch
NCT06721689
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Stephan Grupp MD PhD
NCT05650749
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Roberto Chiarle
NCT06803875
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
Stephan Grupp MD PhD
NCT07007117
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Nationwide Children's Hospital
NCT04211675
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
Emory University
NCT05400603
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Steven DuBois, MD
NCT07027748
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
NCT03794349
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine
NCT03635632
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
NCT01711554
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Neuroblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Neuroblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Neuroblastoma page
10 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Refractory Neuroblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Stephan Grupp MD PhD sponsors the most Refractory Neuroblastoma trials on record, review their full trial history before evaluating a specific study. See Stephan Grupp MD PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Neuroblastoma condition card totals 10 registered trials; most-linked intervention Temozolomide; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.